Abstract
To assess the comparative health and budget impact of low-dose dabigatran indicated for non-valvular atrial fibrillation (AF) population versus reduced doses of apixaban and rivaroxaban in the Netherlands.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
